The recent annual report from NERA Economic Consulting demonstrates the continued focus by the plaintiffs’ securities litigation bar on health care and life science firms, particularly those focused on the development and commercialization of drugs and devices.
The Report found that, excluding merger objections, the Health Technology and Services sector accounted for 25% of all